Atrium Therapeutics, Inc. (RNA)
Nasdaq: RNA · Pharmaceutical Preparations · filing with the SEC since 2025
Who owns Atrium Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Sessa Capital IM, L.P. holds 8.8% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G filed Aug 14, 2026 says.
Directors and officers
11
report now, of 11 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Sessa Capital IM, L.P.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.001 per share
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · 10% in Apr 8, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 5.2% in Apr 27, 2026
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.6% in May 15, 2026
What RNA reports owning in othersstakes of 5% or more, and other ties
Atrium Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.